Jeffrey Zurita

Discovery and Optimization of a STING Agonist Platform for Application in Antibody Drug Conjugates

Jeremy R. Duvall, Joshua D. Thomas, Raghida A. Bukhalid et al. · Journal of Medicinal Chemistry · 2023 · 52 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +17

XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells

Raghida A. Bukhalid, Jeremy R. Duvall, Kelly L. Lancaster et al. · Clinical Cancer Research · 2025 · 36 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Abstract 6706: Systemic administration of STING agonist antibody-drug conjugates elicit potent anti-tumor immune responses with minimal induction of circulating cytokines

Raghida A. Bukhalid, Jeremy R. Duvall, Naniye Mallı Cetinbas et al. · Cancer Research · 2020 · 25 citations

Pharmacy, Immunology, Oncology +16

Abstract 1738: XMT-2056, a well-tolerated, Immunosynthen-based STING-agonist antibody-drug conjugate which induces anti-tumor immune activity

Jeremy R. Duvall, Raghida A. Bukhalid, Naniye Mallı Cetinbas et al. · Cancer Research · 2021 · 24 citations

Pharmacy, Oncology, Pharmacology +17

Abstract 3503: XMT-2056, a HER2-targeted Immunosynthen STING-agonist antibody-drug conjugate, binds a novel epitope of HER2 and shows increased anti-tumor activity in combination with trastuzumab and pertuzumab

Jeremy R. Duvall, Raghida A. Bukhalid, Naniye Mallı Cetinbas et al. · Cancer Research · 2022 · 24 citations

Pharmacy, Oncology, Pharmacology +17